{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-048719","form_type":"8-K","ticker":"A","cik":"0001090872","company_name":"AGILENT TECHNOLOGIES, INC.","filed_at":"2021-09-23T23:59:59+00:00","discovered_at":"2026-05-14T18:04:17.123977+00:00","generated_at":"2026-06-29T01:42:35.750084+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Agilent appoints Pfizer CSO Mikael Dolsten to board effective Sept. 21","bullets":["Dr. Mikael Dolsten, Pfizer CSO & President of Worldwide R&D and Medical, joins Agilent board.","He co-led Pfizer's collaboration with BioNTech on COMIRNATY (COVID-19 vaccine).","Dolsten brings 30+ years pharma experience and involvement in 30+ drug/vaccine approvals.","He will serve on Audit & Finance and Nominating/Corporate Governance committees.","Board size increased from 10 to 11; Dolsten stands for re-election at 2022 annual meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-048719","json":"https://secwatch.observer/filing/0001564590-21-048719.json","markdown":"https://secwatch.observer/filing/0001564590-21-048719.md","text":"https://secwatch.observer/filing/0001564590-21-048719.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1090872/000156459021048719/0001564590-21-048719-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1090872/000156459021048719/a-8k_20210921.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T01:42:35.750084+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"44133b1fcb","claim":"Mikael Dolsten was appointed as Director at AGILENT TECHNOLOGIES, INC..","evidence_excerpt":"appointed Dr. Mikael Dolsten to fill the vacancy so created, both effective September 21, 2021.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1090872/000156459021048719/0001564590-21-048719-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}